Randomized phase 2 trial of a PARP inhibitor TSL-1502 in germline BRCA-mutated, HER2-negative locally advanced/metastatic breast cancer.
- DOI
- 10.1038/s41392-026-02771-9
- Published
- 2026 Aug 10
- Container
- Signal transduction and targeted therapy
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41392-026-02771-9,
title = {Randomized phase 2 trial of a PARP inhibitor TSL-1502 in germline BRCA-mutated, HER2-negative locally advanced/metastatic breast cancer.},
author = {Lan B and Xu F and Sun T and Qiu F and Wang Y and Wang S and Li W and Zhong Y and Wu X and Ouyang Q and Wang K and Mi X and Liu R and Xu B},
year = {2026},
journal = {Signal transduction and targeted therapy},
doi = {10.1038/s41392-026-02771-9},
url = {https://doi.org/10.1038/s41392-026-02771-9}
}RIS
TY - JOUR TI - Randomized phase 2 trial of a PARP inhibitor TSL-1502 in germline BRCA-mutated, HER2-negative locally advanced/metastatic breast cancer. AU - Lan B AU - Xu F AU - Sun T AU - Qiu F AU - Wang Y AU - Wang S AU - Li W AU - Zhong Y AU - Wu X AU - Ouyang Q AU - Wang K AU - Mi X AU - Liu R AU - Xu B PY - 2026 JO - Signal transduction and targeted therapy DO - 10.1038/s41392-026-02771-9 UR - https://doi.org/10.1038/s41392-026-02771-9 ER -
APA
B, L., F, X., T, S., F, Q., Y, W., S, W., W, L., Y, Z., X, W., Q, O., K, W., X, M., R, L., & B, X. (2026). Randomized phase 2 trial of a PARP inhibitor TSL-1502 in germline BRCA-mutated, HER2-negative locally advanced/metastatic breast cancer.. Signal transduction and targeted therapy. https://doi.org/10.1038/s41392-026-02771-9
Source records
- pubmed · retrieved 2026-09-26T07:27:14.969Z